Nitrome Biosciences

Better Lives Through Bold Ideas 

Developing a new class of medicines based on breakthrough discoveries in enzyme biology

Our Method

A New Approach

Nitrome Biosciences is a platform company developing drugs against a newly identified class of enzymes which play a harmful role in a variety of age and inflammation dependent diseases.

The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases including Parkinson’s, a priority indication for the company. The company also aims to expand its proprietary platform to include other diseases, such as other neurodegenerative diseases, macular degeneration, fibrosis and cancer.

Nitrome’s novel approach was featured in the article entitled, “Slowing Down the Effects of Neurological Disorders Using Nitrases.”

About Us

Our Team

It’s about working with the right team of people to discover, innovate, and create new therapies to improve lives.

Read an interview with our CEO Dr. Irene Griswold-Prenner

Irene Griswold-Prenner headshot

In the News

Recognized for Our Work

Want to learn more?

Get in touch to request more information or collaborate.